세계의 패혈증 치료제 시장

Sepsis Therapeutics

발행일: 2024년 08월 | 리서치사:

Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 291 Pages | 배송안내 : 1-2일 (영업일 기준)

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

패혈증 치료제 세계 시장은 2030년까지 71억 달러에 달할 전망

2023년에 46억 달러로 추정되는 패혈증 치료제 세계 시장은 2023-2030년 분석 기간에 CAGR 6.5%로 성장하고 2030년에는 71억 달러에 이를 것으로 예측됩니다. 이 보고서에서 분석한 부문 중 하나인 세팔로스포린 의약품은 CAGR 6.8%로 성장을 지속하고, 분석 기간 종료 시 30억 달러에 달할 것으로 예측됩니다. 당 펩티드 항생제 제약 부문의 성장률은 분석 기간 동안 CAGR 6.2%로 추정됩니다.

미국 시장은 15억 달러로 추정, 중국은 CAGR 8.4%로 성장 예측

미국의 패혈증 치료제 시장은 2023년 15억 달러로 추정됩니다. 세계 2위 경제대국인 중국은 2023-2030년간 CAGR 8.4%로 성장을 지속하여 2030년에는 7억 7,630만 달러 규모에 이를 것으로 예측되고 있습니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 CAGR은 각각 4.7%와 5.6%로 예측되고 있습니다. 유럽에서는 독일이 CAGR 5.8%로 성장할 것으로 예측됩니다.

세계 패혈증 치료제 시장 - 주요 동향 및 촉진요인 요약

패혈증은 감염에 대한 신체의 극단적인 반응으로 인한 생명을 위협하는 병태이며, 높은 사망률과 복잡한 병태 생리로 인해 의료계에서 큰 주목을 받고 있습니다. 패혈증은 신속하게 치료하지 않으면 조직 손상, 장기 부전, 죽음으로 이어질 수 있으므로 패혈증 치료제의 개발이 매우 중요합니다. 종래의 패혈증 치료제에는 주로 광역 항생제와 수액 소생이나 혈관압박 등의 지지요법이 이용되어 왔습니다. 그러나 이러한 접근법은 불충분한 경우가 많으며, 더욱 효과적인 치료법의 긴급한 필요성이 부각되고 있습니다. 패혈증의 근저에 있는 면역학적·분자 생물학적 메커니즘에 대한 이해가 진행되고, 면역 반응의 조절, 혈관 기능의 개선, 장기 기능 부전의 예방을 목적으로 한 신규 치료제의 개발에 박차가 걸려 있습니다.

패혈증 치료제의 현재 상황에는 다양한 연구 약물 및 치료법이 포함됩니다. 단클론항체 및 사이토카인 억제제와 같은 면역조절 요법은 패혈증과 관련된 염증 반응을 완화하도록 설계되었습니다. 또한, 항응고제와 내피 기능을 회복시키는 약제는 패혈증 환자에게 흔히 나타나는 응고 장애나 혈관 누출에 대처하기 위해 연구되고 있습니다. 또한, 세포 기반 치료 및 프레시젼 메디신 접근법과 같은 혁신적인 치료법도 연구되고 있으며, 개별 환자프로파일과 관련된 특정 병원체를 기반으로 치료법을 조정하는 것을 목표로 하고 있습니다. 이러한 신규 치료법의 효능과 안전성을 평가하기 위한 임상시험이 진행 중이며, 일부 유망한 후보 약물은 패혈증 환자의 결과를 크게 개선할 가능성을 보여줍니다.

패혈증 치료제 시장의 성장은 기술 진보, 인지도 향상, 세계 패혈증 발병률 증가 등 여러 요인으로 인해 발생합니다. 차세대 시퀀싱 및 바이오마커 탐색과 같은 기술 혁신은 패혈증을 조기 및 정확하게 진단하는 능력을 향상시켜 표적 치료를 통한 적시 개입을 용이하게 했습니다. 고령화와 만성질환의 만연도 있어 패혈증의 발생률이 세계적으로 증가하고 있기 때문에 효과적인 치료에 대한 수요가 높아지고 있습니다. 또한 조기 패혈증 관리가 매우 중요하다는 인식이 의료 전문가와 환자들 사이에서 확산되어 진단 프로토콜 개선과 보다 적극적인 치료 전략으로 이어지고 있습니다. 게다가 제약기업과 정부기관의 연구개발에 많은 투자가 있어 새로운 패혈증 치료제의 발견과 승인 속도를 가속화하고 시장 성장을 가속하고 있습니다. 그 결과, 패혈증 치료제 시장은 크게 확대되는 태세에 있어, 이 치명적인 질환에 걸린 환자의 관리 개선과 결과에 희망을 가져오고 있습니다.

조사 대상 기업 예(전 45건)

Adrenomed AG
AM-Pharma BV
Asahi Kasei Pharma America
Endacea, Inc.
F. Hoffmann-La Roche Ltd.
GSK Plc
InflaRx NV
Inotrem SA
La Jolla Pharmaceutical Company
TaiRx, Inc.

The global market for Sepsis Therapeutics estimated at US$4.6 Billion in the year 2023, is expected to reach US$7.1 Billion by 2030, growing at a CAGR of 6.5% over the analysis period 2023-2030. Cephalosporin Drugs, one of the segments analyzed in the report, is expected to record a 6.8% CAGR and reach US$3.0 Billion by the end of the analysis period. Growth in the Glycopeptide Antibiotics Drugs segment is estimated at 6.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.5 Billion While China is Forecast to Grow at 8.4% CAGR

The Sepsis Therapeutics market in the U.S. is estimated at US$1.5 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$776.3 Million by the year 2030 trailing a CAGR of 8.4% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.7% and 5.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.8% CAGR.

Global Sepsis Therapeutics Market - Key Trends & Drivers Summarized

Sepsis, a life-threatening condition caused by the body's extreme response to infection, has garnered significant attention in the medical community due to its high mortality rate and complex pathophysiology. The development of sepsis therapeutics is critical as sepsis can lead to tissue damage, organ failure, and death if not treated promptly. Traditional treatments for sepsis have primarily involved broad-spectrum antibiotics and supportive care such as fluid resuscitation and vasopressors. However, these approaches are often insufficient, highlighting the urgent need for more targeted and effective therapies. Advances in our understanding of the immunological and molecular mechanisms underlying sepsis have spurred the development of novel therapeutics aimed at modulating the immune response, improving vascular function, and preventing organ dysfunction.

The current landscape of sepsis therapeutics includes a diverse array of investigational drugs and treatment modalities. Immunomodulatory therapies, such as monoclonal antibodies and cytokine inhibitors, are designed to mitigate the hyperinflammatory response associated with sepsis. Additionally, anticoagulants and agents that restore endothelial function are being explored to address the coagulopathy and vascular leakage commonly seen in sepsis patients. Innovative treatments such as cell-based therapies and precision medicine approaches are also being investigated, aiming to tailor treatments based on individual patient profiles and the specific pathogens involved. Clinical trials are ongoing to evaluate the efficacy and safety of these novel therapies, with several promising candidates showing potential to significantly improve outcomes for sepsis patients.

The growth in the sepsis therapeutics market is driven by several factors, including technological advancements, increased awareness, and the rising incidence of sepsis worldwide. Technological innovations, such as next-generation sequencing and biomarker discovery, have enhanced our ability to diagnose sepsis early and accurately, facilitating timely intervention with targeted therapies. The global increase in the incidence of sepsis, partly due to the aging population and the prevalence of chronic diseases, has heightened the demand for effective treatments. Furthermore, growing awareness among healthcare professionals and patients about the critical importance of early sepsis management has led to improved diagnostic protocols and more aggressive therapeutic strategies. Additionally, substantial investments in research and development by pharmaceutical companies and government agencies are accelerating the pace of discovery and approval of new sepsis therapies, driving market growth. As a result, the sepsis therapeutics market is poised for significant expansion, offering hope for better management and outcomes for patients affected by this devastating condition.

Select Competitors (Total 45 Featured) -

Adrenomed AG
AM-Pharma B.V.
Asahi Kasei Pharma America
Endacea, Inc.
F. Hoffmann-La Roche Ltd.
GSK Plc
InflaRx N.V.
Inotrem SA
La Jolla Pharmaceutical Company
TaiRx, Inc.

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
- Sepsis: A Life-Threatening Condition Requiring Urgent Action
- Interventions for Managing Sepsis
- Treatments that are Commonly Applied for Sepsis
- Global Economic Update
- Competitive Landscape
- Sepsis Therapeutics - Global Key Competitors Percentage Market Share in 2024 (E)
- Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
- Global Market Prospects and Outlook
- Thriving Global Sepsis Therapeutics Market Oozes Signs of Robust Health
- Cephalosporins Hold a Major Share of the Treatment Market
- Global Sepsis Therapeutics Market Receives Pulsating Impetus from North America, Asia-Pacific to Witness Fastest Growth
- Limited Therapeutic Options: A Challenge
- Antibiotics and Vasopressors - The Current Standard of Care
- Current Categories of Antibacterial Agents for First-line Sepsis Treatment
- Current Anti-bacterial Drugs used in Sepsis
- Current Antifungals used for Sepsis
- GIAPREZA - The Only FDA Approved Branded Drug for Sepsis Treatment
- Promising Treatment for Sepsis
- Recent Market Activity
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
- Rising Incidence of Sepsis Propels Market Growth
- Aging Population: A Key Growth Driver for Sepsis Therapeutics
- Global Aging Population Statistics for the 65+ Age Group in Million by Geographic Region for the Years 2019, 2025, 2035 and 2050
- A Market Characterized by High Unmet Medical Needs
- Novel Immune-Specific Modes of Action under Focus
- Emphasizing on Endothelial Cell Function
- HMGB1- A Potential Target for Future Therapies
- Hydrocortisone Displays Potential in Septic Shock Treatment
- Reduced Levels of Vitamin C Characterize Sepsis Patients
- Treatment with Hydrocortisone and Vitamin C Demonstrates Positive Impact on Mortality Rate
- Intravenous Vitamins + Hydrocortisone Therapy Causes Waves in the Market
- Anticancer Drugs - Offering Potential Treatment of Sepsis
- New Protein to be Effective for Sepsis
- Rise in Healthcare Expenditure to Drive Growth
- World Healthcare Expenditure (In US$ Billion) for the Years 2017-2023
- AI-Driven Sepsis Screening Approach to Save Lives
- Increasing R&D Activity & New Product Launches Spur Market Growth
- Purdue Researchers Develop IV Injection for Sepsis
- PLK1-mTOR Axis - A Potential Therapeutic for Sepsis
- New Nanoparticles - A Revolution in the Development of Clinical Sepsis Therapy
- Strong Pipeline and Increased Research Activity Enables Increased Awareness of Disease Pathogenesis
4. GLOBAL MARKET PERSPECTIVE
- TABLE 1: World Sepsis Therapeutics Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
- TABLE 2: World Recent Past, Current & Future Analysis for Sepsis Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
- TABLE 3: World Historic Review for Sepsis Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 4: World 16-Year Perspective for Sepsis Therapeutics by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
- TABLE 5: World Recent Past, Current & Future Analysis for Cephalosporin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
- TABLE 6: World Historic Review for Cephalosporin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 7: World 16-Year Perspective for Cephalosporin by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
- TABLE 8: World Recent Past, Current & Future Analysis for Glycopeptide Antibiotics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
- TABLE 9: World Historic Review for Glycopeptide Antibiotics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 10: World 16-Year Perspective for Glycopeptide Antibiotics by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
- TABLE 11: World Recent Past, Current & Future Analysis for Aminoglycosides by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
- TABLE 12: World Historic Review for Aminoglycosides by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 13: World 16-Year Perspective for Aminoglycosides by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
- TABLE 14: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
- TABLE 15: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 16: World 16-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
- TABLE 17: World Recent Past, Current & Future Analysis for Intravenous by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
- TABLE 18: World Historic Review for Intravenous by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 19: World 16-Year Perspective for Intravenous by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
- TABLE 20: World Recent Past, Current & Future Analysis for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
- TABLE 21: World Historic Review for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 22: World 16-Year Perspective for Oral by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

UNITED STATES
- Sepsis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
- TABLE 23: USA Recent Past, Current & Future Analysis for Sepsis Therapeutics by Drug Class - Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 24: USA Historic Review for Sepsis Therapeutics by Drug Class - Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 25: USA 16-Year Perspective for Sepsis Therapeutics by Drug Class - Percentage Breakdown of Value Revenues for Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes for the Years 2014, 2024 & 2030
- TABLE 26: USA Recent Past, Current & Future Analysis for Sepsis Therapeutics by Route Of Administration - Intravenous and Oral - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 27: USA Historic Review for Sepsis Therapeutics by Route Of Administration - Intravenous and Oral Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 28: USA 16-Year Perspective for Sepsis Therapeutics by Route Of Administration - Percentage Breakdown of Value Revenues for Intravenous and Oral for the Years 2014, 2024 & 2030
CANADA
- TABLE 29: Canada Recent Past, Current & Future Analysis for Sepsis Therapeutics by Drug Class - Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 30: Canada Historic Review for Sepsis Therapeutics by Drug Class - Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 31: Canada 16-Year Perspective for Sepsis Therapeutics by Drug Class - Percentage Breakdown of Value Revenues for Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes for the Years 2014, 2024 & 2030
- TABLE 32: Canada Recent Past, Current & Future Analysis for Sepsis Therapeutics by Route Of Administration - Intravenous and Oral - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 33: Canada Historic Review for Sepsis Therapeutics by Route Of Administration - Intravenous and Oral Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 34: Canada 16-Year Perspective for Sepsis Therapeutics by Route Of Administration - Percentage Breakdown of Value Revenues for Intravenous and Oral for the Years 2014, 2024 & 2030
JAPAN
- Sepsis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
- TABLE 35: Japan Recent Past, Current & Future Analysis for Sepsis Therapeutics by Drug Class - Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 36: Japan Historic Review for Sepsis Therapeutics by Drug Class - Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 37: Japan 16-Year Perspective for Sepsis Therapeutics by Drug Class - Percentage Breakdown of Value Revenues for Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes for the Years 2014, 2024 & 2030
- TABLE 38: Japan Recent Past, Current & Future Analysis for Sepsis Therapeutics by Route Of Administration - Intravenous and Oral - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 39: Japan Historic Review for Sepsis Therapeutics by Route Of Administration - Intravenous and Oral Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 40: Japan 16-Year Perspective for Sepsis Therapeutics by Route Of Administration - Percentage Breakdown of Value Revenues for Intravenous and Oral for the Years 2014, 2024 & 2030
CHINA
- Sepsis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
- TABLE 41: China Recent Past, Current & Future Analysis for Sepsis Therapeutics by Drug Class - Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 42: China Historic Review for Sepsis Therapeutics by Drug Class - Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 43: China 16-Year Perspective for Sepsis Therapeutics by Drug Class - Percentage Breakdown of Value Revenues for Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes for the Years 2014, 2024 & 2030
- TABLE 44: China Recent Past, Current & Future Analysis for Sepsis Therapeutics by Route Of Administration - Intravenous and Oral - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 45: China Historic Review for Sepsis Therapeutics by Route Of Administration - Intravenous and Oral Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 46: China 16-Year Perspective for Sepsis Therapeutics by Route Of Administration - Percentage Breakdown of Value Revenues for Intravenous and Oral for the Years 2014, 2024 & 2030
EUROPE
- Sepsis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
- TABLE 47: Europe Recent Past, Current & Future Analysis for Sepsis Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
- TABLE 48: Europe Historic Review for Sepsis Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 49: Europe 16-Year Perspective for Sepsis Therapeutics by Geographic Region - Percentage Breakdown of Value Revenues for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
- TABLE 50: Europe Recent Past, Current & Future Analysis for Sepsis Therapeutics by Drug Class - Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 51: Europe Historic Review for Sepsis Therapeutics by Drug Class - Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 52: Europe 16-Year Perspective for Sepsis Therapeutics by Drug Class - Percentage Breakdown of Value Revenues for Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes for the Years 2014, 2024 & 2030
- TABLE 53: Europe Recent Past, Current & Future Analysis for Sepsis Therapeutics by Route Of Administration - Intravenous and Oral - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 54: Europe Historic Review for Sepsis Therapeutics by Route Of Administration - Intravenous and Oral Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 55: Europe 16-Year Perspective for Sepsis Therapeutics by Route Of Administration - Percentage Breakdown of Value Revenues for Intravenous and Oral for the Years 2014, 2024 & 2030
FRANCE
- Sepsis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
- TABLE 56: France Recent Past, Current & Future Analysis for Sepsis Therapeutics by Drug Class - Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 57: France Historic Review for Sepsis Therapeutics by Drug Class - Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 58: France 16-Year Perspective for Sepsis Therapeutics by Drug Class - Percentage Breakdown of Value Revenues for Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes for the Years 2014, 2024 & 2030
- TABLE 59: France Recent Past, Current & Future Analysis for Sepsis Therapeutics by Route Of Administration - Intravenous and Oral - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 60: France Historic Review for Sepsis Therapeutics by Route Of Administration - Intravenous and Oral Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 61: France 16-Year Perspective for Sepsis Therapeutics by Route Of Administration - Percentage Breakdown of Value Revenues for Intravenous and Oral for the Years 2014, 2024 & 2030
GERMANY
- Sepsis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
- TABLE 62: Germany Recent Past, Current & Future Analysis for Sepsis Therapeutics by Drug Class - Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 63: Germany Historic Review for Sepsis Therapeutics by Drug Class - Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 64: Germany 16-Year Perspective for Sepsis Therapeutics by Drug Class - Percentage Breakdown of Value Revenues for Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes for the Years 2014, 2024 & 2030
- TABLE 65: Germany Recent Past, Current & Future Analysis for Sepsis Therapeutics by Route Of Administration - Intravenous and Oral - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 66: Germany Historic Review for Sepsis Therapeutics by Route Of Administration - Intravenous and Oral Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 67: Germany 16-Year Perspective for Sepsis Therapeutics by Route Of Administration - Percentage Breakdown of Value Revenues for Intravenous and Oral for the Years 2014, 2024 & 2030
ITALY
- TABLE 68: Italy Recent Past, Current & Future Analysis for Sepsis Therapeutics by Drug Class - Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 69: Italy Historic Review for Sepsis Therapeutics by Drug Class - Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 70: Italy 16-Year Perspective for Sepsis Therapeutics by Drug Class - Percentage Breakdown of Value Revenues for Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes for the Years 2014, 2024 & 2030
- TABLE 71: Italy Recent Past, Current & Future Analysis for Sepsis Therapeutics by Route Of Administration - Intravenous and Oral - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 72: Italy Historic Review for Sepsis Therapeutics by Route Of Administration - Intravenous and Oral Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 73: Italy 16-Year Perspective for Sepsis Therapeutics by Route Of Administration - Percentage Breakdown of Value Revenues for Intravenous and Oral for the Years 2014, 2024 & 2030
UNITED KINGDOM
- Sepsis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
- TABLE 74: UK Recent Past, Current & Future Analysis for Sepsis Therapeutics by Drug Class - Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 75: UK Historic Review for Sepsis Therapeutics by Drug Class - Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 76: UK 16-Year Perspective for Sepsis Therapeutics by Drug Class - Percentage Breakdown of Value Revenues for Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes for the Years 2014, 2024 & 2030
- TABLE 77: UK Recent Past, Current & Future Analysis for Sepsis Therapeutics by Route Of Administration - Intravenous and Oral - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 78: UK Historic Review for Sepsis Therapeutics by Route Of Administration - Intravenous and Oral Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 79: UK 16-Year Perspective for Sepsis Therapeutics by Route Of Administration - Percentage Breakdown of Value Revenues for Intravenous and Oral for the Years 2014, 2024 & 2030
SPAIN
- TABLE 80: Spain Recent Past, Current & Future Analysis for Sepsis Therapeutics by Drug Class - Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 81: Spain Historic Review for Sepsis Therapeutics by Drug Class - Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 82: Spain 16-Year Perspective for Sepsis Therapeutics by Drug Class - Percentage Breakdown of Value Revenues for Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes for the Years 2014, 2024 & 2030
- TABLE 83: Spain Recent Past, Current & Future Analysis for Sepsis Therapeutics by Route Of Administration - Intravenous and Oral - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 84: Spain Historic Review for Sepsis Therapeutics by Route Of Administration - Intravenous and Oral Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 85: Spain 16-Year Perspective for Sepsis Therapeutics by Route Of Administration - Percentage Breakdown of Value Revenues for Intravenous and Oral for the Years 2014, 2024 & 2030
RUSSIA
- TABLE 86: Russia Recent Past, Current & Future Analysis for Sepsis Therapeutics by Drug Class - Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 87: Russia Historic Review for Sepsis Therapeutics by Drug Class - Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 88: Russia 16-Year Perspective for Sepsis Therapeutics by Drug Class - Percentage Breakdown of Value Revenues for Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes for the Years 2014, 2024 & 2030
- TABLE 89: Russia Recent Past, Current & Future Analysis for Sepsis Therapeutics by Route Of Administration - Intravenous and Oral - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 90: Russia Historic Review for Sepsis Therapeutics by Route Of Administration - Intravenous and Oral Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 91: Russia 16-Year Perspective for Sepsis Therapeutics by Route Of Administration - Percentage Breakdown of Value Revenues for Intravenous and Oral for the Years 2014, 2024 & 2030
REST OF EUROPE
- TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Sepsis Therapeutics by Drug Class - Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 93: Rest of Europe Historic Review for Sepsis Therapeutics by Drug Class - Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 94: Rest of Europe 16-Year Perspective for Sepsis Therapeutics by Drug Class - Percentage Breakdown of Value Revenues for Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes for the Years 2014, 2024 & 2030
- TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Sepsis Therapeutics by Route Of Administration - Intravenous and Oral - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 96: Rest of Europe Historic Review for Sepsis Therapeutics by Route Of Administration - Intravenous and Oral Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 97: Rest of Europe 16-Year Perspective for Sepsis Therapeutics by Route Of Administration - Percentage Breakdown of Value Revenues for Intravenous and Oral for the Years 2014, 2024 & 2030
ASIA-PACIFIC
- Sepsis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
- TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Sepsis Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
- TABLE 99: Asia-Pacific Historic Review for Sepsis Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 100: Asia-Pacific 16-Year Perspective for Sepsis Therapeutics by Geographic Region - Percentage Breakdown of Value Revenues for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
- TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Sepsis Therapeutics by Drug Class - Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 102: Asia-Pacific Historic Review for Sepsis Therapeutics by Drug Class - Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 103: Asia-Pacific 16-Year Perspective for Sepsis Therapeutics by Drug Class - Percentage Breakdown of Value Revenues for Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes for the Years 2014, 2024 & 2030
- TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Sepsis Therapeutics by Route Of Administration - Intravenous and Oral - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 105: Asia-Pacific Historic Review for Sepsis Therapeutics by Route Of Administration - Intravenous and Oral Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 106: Asia-Pacific 16-Year Perspective for Sepsis Therapeutics by Route Of Administration - Percentage Breakdown of Value Revenues for Intravenous and Oral for the Years 2014, 2024 & 2030
AUSTRALIA
- Sepsis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
- TABLE 107: Australia Recent Past, Current & Future Analysis for Sepsis Therapeutics by Drug Class - Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 108: Australia Historic Review for Sepsis Therapeutics by Drug Class - Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 109: Australia 16-Year Perspective for Sepsis Therapeutics by Drug Class - Percentage Breakdown of Value Revenues for Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes for the Years 2014, 2024 & 2030
- TABLE 110: Australia Recent Past, Current & Future Analysis for Sepsis Therapeutics by Route Of Administration - Intravenous and Oral - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 111: Australia Historic Review for Sepsis Therapeutics by Route Of Administration - Intravenous and Oral Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 112: Australia 16-Year Perspective for Sepsis Therapeutics by Route Of Administration - Percentage Breakdown of Value Revenues for Intravenous and Oral for the Years 2014, 2024 & 2030
INDIA
- Sepsis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
- TABLE 113: India Recent Past, Current & Future Analysis for Sepsis Therapeutics by Drug Class - Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 114: India Historic Review for Sepsis Therapeutics by Drug Class - Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 115: India 16-Year Perspective for Sepsis Therapeutics by Drug Class - Percentage Breakdown of Value Revenues for Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes for the Years 2014, 2024 & 2030
- TABLE 116: India Recent Past, Current & Future Analysis for Sepsis Therapeutics by Route Of Administration - Intravenous and Oral - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 117: India Historic Review for Sepsis Therapeutics by Route Of Administration - Intravenous and Oral Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 118: India 16-Year Perspective for Sepsis Therapeutics by Route Of Administration - Percentage Breakdown of Value Revenues for Intravenous and Oral for the Years 2014, 2024 & 2030
SOUTH KOREA
- TABLE 119: South Korea Recent Past, Current & Future Analysis for Sepsis Therapeutics by Drug Class - Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 120: South Korea Historic Review for Sepsis Therapeutics by Drug Class - Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 121: South Korea 16-Year Perspective for Sepsis Therapeutics by Drug Class - Percentage Breakdown of Value Revenues for Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes for the Years 2014, 2024 & 2030
- TABLE 122: South Korea Recent Past, Current & Future Analysis for Sepsis Therapeutics by Route Of Administration - Intravenous and Oral - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 123: South Korea Historic Review for Sepsis Therapeutics by Route Of Administration - Intravenous and Oral Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 124: South Korea 16-Year Perspective for Sepsis Therapeutics by Route Of Administration - Percentage Breakdown of Value Revenues for Intravenous and Oral for the Years 2014, 2024 & 2030
REST OF ASIA-PACIFIC
- TABLE 125: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Sepsis Therapeutics by Drug Class - Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 126: Rest of Asia-Pacific Historic Review for Sepsis Therapeutics by Drug Class - Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 127: Rest of Asia-Pacific 16-Year Perspective for Sepsis Therapeutics by Drug Class - Percentage Breakdown of Value Revenues for Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes for the Years 2014, 2024 & 2030
- TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Sepsis Therapeutics by Route Of Administration - Intravenous and Oral - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 129: Rest of Asia-Pacific Historic Review for Sepsis Therapeutics by Route Of Administration - Intravenous and Oral Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 130: Rest of Asia-Pacific 16-Year Perspective for Sepsis Therapeutics by Route Of Administration - Percentage Breakdown of Value Revenues for Intravenous and Oral for the Years 2014, 2024 & 2030
LATIN AMERICA
- Sepsis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
- TABLE 131: Latin America Recent Past, Current & Future Analysis for Sepsis Therapeutics by Drug Class - Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 132: Latin America Historic Review for Sepsis Therapeutics by Drug Class - Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 133: Latin America 16-Year Perspective for Sepsis Therapeutics by Drug Class - Percentage Breakdown of Value Revenues for Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes for the Years 2014, 2024 & 2030
- TABLE 134: Latin America Recent Past, Current & Future Analysis for Sepsis Therapeutics by Route Of Administration - Intravenous and Oral - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 135: Latin America Historic Review for Sepsis Therapeutics by Route Of Administration - Intravenous and Oral Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 136: Latin America 16-Year Perspective for Sepsis Therapeutics by Route Of Administration - Percentage Breakdown of Value Revenues for Intravenous and Oral for the Years 2014, 2024 & 2030
MIDDLE EAST
- Sepsis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
- TABLE 137: Middle East Recent Past, Current & Future Analysis for Sepsis Therapeutics by Drug Class - Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 138: Middle East Historic Review for Sepsis Therapeutics by Drug Class - Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 139: Middle East 16-Year Perspective for Sepsis Therapeutics by Drug Class - Percentage Breakdown of Value Revenues for Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes for the Years 2014, 2024 & 2030
- TABLE 140: Middle East Recent Past, Current & Future Analysis for Sepsis Therapeutics by Route Of Administration - Intravenous and Oral - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 141: Middle East Historic Review for Sepsis Therapeutics by Route Of Administration - Intravenous and Oral Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 142: Middle East 16-Year Perspective for Sepsis Therapeutics by Route Of Administration - Percentage Breakdown of Value Revenues for Intravenous and Oral for the Years 2014, 2024 & 2030
AFRICA
- Sepsis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
- TABLE 143: Africa Recent Past, Current & Future Analysis for Sepsis Therapeutics by Drug Class - Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 144: Africa Historic Review for Sepsis Therapeutics by Drug Class - Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 145: Africa 16-Year Perspective for Sepsis Therapeutics by Drug Class - Percentage Breakdown of Value Revenues for Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes for the Years 2014, 2024 & 2030
- TABLE 146: Africa Recent Past, Current & Future Analysis for Sepsis Therapeutics by Route Of Administration - Intravenous and Oral - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 147: Africa Historic Review for Sepsis Therapeutics by Route Of Administration - Intravenous and Oral Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 148: Africa 16-Year Perspective for Sepsis Therapeutics by Route Of Administration - Percentage Breakdown of Value Revenues for Intravenous and Oral for the Years 2014, 2024 & 2030